Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
Vandana Ayyar Gupta, Jacqueline Pitchforth, Joana Domingos, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0283669-e0283669
Open Access | Times Cited: 17

Showing 17 citing articles:

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Eugenio Mercuri, Juan J. Vílchez, Odile Boespflug‐Tanguy, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 4, pp. 393-403
Closed Access | Times Cited: 43
Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy
Michael Rabbia, Maitea Guridi Ormazabal, Hannah Staunton, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 3, pp. 701-714
Open Access | Times Cited: 9
Fully personalized modelling of Duchenne Muscular Dystrophy ambulation
Victor Applebaum, Evan Baker, Thomas J. Kim, et al.
Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences (2025) Vol. 383, Iss. 2293
Open Access | Times Cited: 1
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 6
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304984-e0304984
Open Access | Times Cited: 5
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Bettina Henzi, Simone Schmidt, Sara Nagy, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 10, pp. 890-899
Closed Access | Times Cited: 12
A patient-centered qualitative evaluation of meaningful change on the NSAA and PUL in Duchenne Muscular Dystrophy
Arielle S. Gillman, Teofil Ciobanu, Louise Barrett, et al.
Frontiers in Neurology (2025) Vol. 16
Open Access
Radiomics with Ultrasound Radiofrequency Data for Improving Evaluation of Duchenne Muscular Dystrophy
Dong Yan, Qiang Li, Ya‐Wen Chuang, et al.
Deleted Journal (2025)
Closed Access
Gene therapy approval for Duchenne muscular dystrophy: a European perspective
Hannah Jolly, Annemieke Aartsma‐Rus, Enrico Bertini, et al.
The Lancet (2025) Vol. 405, Iss. 10489, pp. 1572-1573
Closed Access
Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus
Maryam Oskoui, Tracie A. Caller, Julie Parsons, et al.
Neurology (2025) Vol. 104, Iss. 11
Closed Access
A systematic review on motor outcome measures in Congenital Myopathy
Matthew Woods, Gemma Fisher, Sarah Johnson, et al.
Neuromuscular Disorders (2025), pp. 105392-105392
Closed Access
Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys
Georgia Stimpson, Deborah Ridout, Amy Wolfe, et al.
Journal of Neuromuscular Diseases (2023) Vol. 11, Iss. 1, pp. 153-166
Open Access | Times Cited: 9
Outcome Measures in Duchenne Muscular Dystrophy
Silvia Benemei, Francesca Gatto, Luca Boni, et al.
Acta Neurologica Belgica (2024)
Open Access | Times Cited: 2
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review
Carlos Pascual‐Morena, Maribel Lucerón‐Lucas‐Torres, Irene Martínez‐García, et al.
Pediatric Drugs (2024)
Closed Access | Times Cited: 2
AAV gene therapy for Duchenne Muscular Dystrophy: lessons learned from a phase 3 trial
Giovanni Baranello, Francesco Muntoni
Gene Therapy (2024) Vol. 31, Iss. 11-12, pp. 541-543
Closed Access | Times Cited: 2
Understanding North Star Ambulatory Assessment total scores and their implications for standards of care using observational data
Georgia Stimpson, M. James, Michela Guglieri, et al.
European Journal of Paediatric Neurology (2024) Vol. 53, pp. 123-130
Open Access | Times Cited: 1
Clinical importance of changes in magnetic resonance biomarkers for Duchenne muscular dystrophy
Rebecca J. Willcocks, Alison M. Barnard, Michael J. Daniels, et al.
Annals of Clinical and Translational Neurology (2023) Vol. 11, Iss. 1, pp. 67-78
Open Access | Times Cited: 2
Appendicular lean mass index and motor function in ambulatory patients with Duchenne muscular dystrophy
Michael Kiefer, Elise L. Townsend, C. Goncalves, et al.
Muscle & Nerve (2024) Vol. 70, Iss. 2, pp. 226-231
Open Access
“Natural history of skeletal muscle laminopathies: a 2-year prospective study”
Luca Spiro Santovito, Silvia Bonanno, Maria Barbara Pasanisi, et al.
Neuromuscular Disorders (2024) Vol. 47, pp. 105256-105256
Closed Access
Page 1

Scroll to top